Clinical Trials /

Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma

NCT01849146

Description:

This phase I trial studies the side effects and best dose of adavosertib when given together with radiation therapy and temozolomide in treating patients with glioblastoma that is newly diagnosed or has come back. Adavosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving adavosertib, radiation therapy, and temozolomide may work better in treating patients with newly diagnosed or recurrent glioblastoma compared to radiation therapy and temozolomide alone.

Related Conditions:
  • Glioblastoma
Recruiting Status:

Active, not recruiting

Phase:

Phase 1

Trial Eligibility

Document

Title

  • Brief Title: Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma
  • Official Title: Phase I Study of AZD1775 (Adavosertib) With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients With Recurrent Glioblastoma

Clinical Trial IDs

  • ORG STUDY ID: NCI-2013-00858
  • SECONDARY ID: NCI-2013-00858
  • SECONDARY ID: ABTC 1202
  • SECONDARY ID: ABTC-1202
  • SECONDARY ID: ABTC-1202
  • SECONDARY ID: UM1CA137443
  • NCT ID: NCT01849146

Conditions

  • Glioblastoma
  • Recurrent Glioblastoma

Interventions

DrugSynonymsArms
AdavosertibAZD-1775, AZD1775, MK-1775, MK1775Arm I (adavosertib, temozolomide, radiation)
TemozolomideCCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZArm I (adavosertib, temozolomide, radiation)

Purpose

This phase I trial studies the side effects and best dose of adavosertib when given together with radiation therapy and temozolomide in treating patients with glioblastoma that is newly diagnosed or has come back. Adavosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving adavosertib, radiation therapy, and temozolomide may work better in treating patients with newly diagnosed or recurrent glioblastoma compared to radiation therapy and temozolomide alone.

Detailed Description

      PRIMARY OBJECTIVES:

      I. To determine the maximum tolerated doses (MTD) of AZD1775 (adavosertib) in combination
      with the current standard of care (radiotherapy/temozolomide for concomitant therapy and
      temozolomide for adjuvant therapy) for treating patients with newly diagnosed glioblastoma.

      II. To define the MTD of AZD1775 (adavosertib) in combination with 6 weeks of daily
      (Monday-Friday [M-F]) radiotherapy (RT) and concomitant temozolomide (TMZ) administered at 75
      mg/m^2/day in patients with newly diagnosed glioblastoma. (Arm 1) III. To define the MTD of
      AZD1775 (adavosertib) in combination with adjuvant TMZ administered at 150 mg/m^2/day-200
      mg/m^2/day for 5 days every 28 days in patients with glioblastoma after concurrent RT/TMZ.
      (Arm 2)

      SECONDARY OBJECTIVES:

      I. To characterize the safety profile of AZD1775 (adavosertib) in combination with RT and
      concomitant TMZ (Arm 1) and AZD1775 (adavosertib) with adjuvant TMZ (Arm 2) in patients with
      newly diagnosed glioblastoma.

      II. To assess the pharmacokinetic (PK) profile of AZD1775 (adavosertib) in combination with
      upfront radiation/TMZ and adjuvant TMZ in patients with newly diagnosed glioblastoma.

      INTRATUMORAL CORRELATIVES/PHARMACOKINETICS OBJECTIVES:

      I. To determine the intratumoral concentration of AZD1775 (adavosertib) achieved in patients
      treated with the putative MTD.

      II. To characterize the time course of AZD1775 (adavosertib) in extracellular fluid within
      brain tumors following a single oral dose of drug by microdialysis.

      III. To characterize the pharmacodynamic effects of AZD1775 on tumor through
      immunohistochemistry (IHC) analysis of pRb (S807/811), proliferation (e.g. Ki-67), pCDC2,
      Wee1, and apoptosis (e.g. cleaved caspase 3) on resected tumors exposed to drug.

      IV. To characterize MGMT methylation and P53 pathway status, also P-gp and wee1 expression
      levels in patients with newly diagnosed glioblastoma treated with standard therapy in
      combination with AZD1775 (adavosertib).

      V. To explore and analyze adaptive resistance mechanisms to AZD1775 using proteogenomics, and
      connect this data to spatially resolved drug distribution through targeted, imaging-based
      quantification of drug efficacy and tumor response.

      OUTLINE: This is a dose-escalation study of adavosertib. Patients are assigned to 1 of 2
      treatment arms.

      ARM I:

      INITIATION CYCLE: Patients receive adavosertib orally (PO) on days 1, 3, and 5 or days 1-5
      weekly and temozolomide PO once daily (QD) for 6 weeks. Patients also undergo concurrent
      radiation therapy 5 days per week for 6 weeks.

      MAINTENANCE CYCLES: Beginning in week 10, patients receive temozolomide PO QD on days 1-5.
      Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or
      unacceptable toxicity.

      ARM II: Patients receive adavosertib PO QD on days 1, 3, and 5 or 1-5 weekly, and
      temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 6 cycles in the
      absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 2 months for 2 years, and
      then every 6 months thereafter.
    

Trial Arms

NameTypeDescriptionInterventions
Arm I (adavosertib, temozolomide, radiation)ExperimentalINITIATION CYCLE: Patients receive adavosertib PO on days 1, 3, and 5 or 1-5 weekly and temozolomide PO QD for 6 weeks. Patients also undergo concurrent radiation therapy 5 days per week for 6 weeks. MAINTENANCE CYCLES: Beginning in week 10, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
  • Adavosertib
  • Temozolomide
Arm II (adavosertib, temozolomide)ExperimentalPatients receive adavosertib PO QD on days 1, 3, and 5 or 1-5 weekly, and temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
  • Adavosertib
  • Temozolomide

Eligibility Criteria

        Inclusion Criteria:

          -  Patients must have a tumor tissue form indicating availability of archived tissue from
             initial resection at diagnosis of glioblastoma completed and signed by a pathologist

          -  Patients must have a Karnofsky performance status >= 60% (i.e. the patient must be
             able to care for himself/herself with occasional help from others)

          -  Absolute neutrophil count >= 1,500/mcL

          -  Platelets >= 100,000/mcL

          -  Hemoglobin >= 9 g/dL

          -  Total bilirubin =< institutional upper limit of normal

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =< 3 x institutional upper limit of normal; if above the institutional upper limit of
             normal but =< 3 times institutional upper limit of normal, the decision to initiate
             temozolomide treatment should carefully consider the benefits and risks for the
             individual patient

          -  Creatinine =< institutional upper limit of normal OR creatinine clearance >= 60
             ml/min/1.73 m^2 for patients with creatinine levels above institutional normal

          -  Activated partial thromboplastin time (APTT)/partial thromboplastin time (PTT) =< 1.5
             x institutional upper limit of normal

          -  Patients must be able to provide written informed consent

          -  Patients must have magnetic resonance imaging (MRI) within 21 days of starting
             treatment

          -  Women of childbearing potential must have a negative serum pregnancy test prior to
             study entry; women of childbearing potential and men must agree to use two birth
             control methods (either two barrier methods or a barrier method plus a hormonal
             method) or abstinence prior to study entry and for the duration of study
             participation; should a woman become pregnant or suspect she is pregnant while
             participating in this study, she should inform her treating physician immediately

          -  Patients must have no concurrent malignancy except curatively treated basal or
             squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or
             bladder; patients with prior malignancies must be disease-free for >= five years

          -  Patients must be maintained on a stable corticosteroid regimen (no increase for 5
             days) prior to the start of treatment

          -  Patients must be able to swallow whole capsules

          -  PHASE I PATIENTS:

          -  Must have histologically proven glioblastoma

          -  Must have recovered from the immediate post-operative period

          -  Patients going on Arm 1 or combination dose cohort must not have received prior
             radiation therapy, chemotherapy, immunotherapy or therapy with biologic agent
             (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists,
             interferons, interleukins, tumor infiltrating lymphocytes [TIL], lymphokine-activated
             killer [LAK] or gene therapy), or hormonal therapy for their brain tumor;
             glucocorticoid therapy is allowed

          -  Patients going on Arm 2 must have received planned treatment with radiation therapy
             and concomitant temozolomide at least 28 days but no more than 49 days prior to
             starting treatment on this study; patients must have received at least 80% of planned
             temozolomide and radiation therapy with no grade 3 or grade 4 toxicity (except
             lymphopenia) attributed to the temozolomide; Arm 2 patients may not have received any
             other prior chemotherapy, immunotherapy or therapy with biologic agent (including
             immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons,
             interleukins, TIL, LAK or gene therapy), or hormonal therapy for their brain tumor;
             prior Gliadel wafers are allowed; glucocorticoid therapy is allowed

          -  INTRATUMORAL DRUG DISTRIBUTION STUDY PATIENTS:

          -  Patients must have prior histologically proven glioblastoma that is progressive or
             recurrent following radiation therapy +/- chemotherapy

          -  Patients must be undergoing repeat surgery that is clinically indicated as determined
             by their care providers

          -  Patients must have measurable contrast-enhancing progressive or recurrent glioblastoma
             by MRI within 21 days of starting treatment; patient must be able to tolerate MRIs

          -  Patients may have an unlimited number of prior therapy regimens

          -  Patients must have recovered from severe toxicity of prior therapy; the following
             intervals from previous treatments are required to be eligible:

               -  12 weeks from the completion of radiation

               -  6 weeks from a nitrosourea chemotherapy

               -  3 weeks from a non-nitrosourea chemotherapy

               -  4 weeks from any investigational (not Food and Drug Administration
                  [FDA]-approved) agents

               -  2 weeks from administration of a non-cytotoxic, FDA-approved agent (e.g.,
                  Tarceva, hydroxychloroquine, bevacizumab, etc.)

        Exclusion Criteria:

          -  Patients receiving any other investigational agents are ineligible

          -  Patients with a history of allergic reactions attributed to compounds of similar
             chemical or biologic composition to temozolomide or AZD1775 (adavosertib) are
             ineligible; the AZD1775 (adavosertib) investigator brochure and the temozolomide
             package insert can be referenced for more information

          -  Patients on enzyme-inducing anti-epileptic drugs (EIAED) are not eligible for
             treatment on this protocol; patients may be on non-enzyme inducing anti-epileptic
             drugs or not be taking any anti-epileptic drugs; patients previously treated with
             EIAED may be enrolled if they have been off the EIAED for 10 days or more prior to the
             first dose of AZD1775 (adavosertib)

          -  Patients may not be on drugs known to be moderate or potent inhibitors/inducers of
             CYP3A4, sensitive substrates of CYP3A4, or substrates of CYP3A4 with narrow
             therapeutic windows

          -  Patients may not be on anti-coagulants (warfarin, etc.) other than low-molecular
             weight heparin (LMWH)

          -  Patients with uncontrolled intercurrent illness including, but not limited to, ongoing
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,
             cardiac arrhythmia, or psychiatric illness/social situations that would limit
             compliance with study requirements, are ineligible

          -  Pregnant women are excluded from this study because AZD1775 (adavosertib) has
             potential for teratogenic or abortifacients effects; because there is an unknown but
             potential risk for adverse events in nursing infants secondary to treatment of the
             mother with AZD1775 (adavosertib), breastfeeding should be discontinued if the mother
             is treated with AZD1775 (adavosertib)

          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
             therapy are ineligible because of the potential for pharmacokinetic interactions with
             AZD1775 (adavosertib); in addition, these patients are at increased risk of lethal
             infections when treated with marrow-suppressive therapy
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Maximum tolerated dose of adavosertib with 6 weeks of radiotherapy and temozolomide (Arm I)
Time Frame:Up to 6 weeks
Safety Issue:
Description:Will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Severity and frequency of toxicity will be tabulated by the tested dose or doses using descriptive statistics. The proportion of subjects who experience grade 3 or above toxicities will be estimated, along with 95% confidence intervals by each type of toxicity.

Secondary Outcome Measures

Measure:Overall survival
Time Frame:The time from the date of initial diagnosis to the date of death, assessed up to 2 years
Safety Issue:
Description:Calculated using the Kaplan-Meier method.
Measure:Progression-free survival
Time Frame:The time from the date of initial diagnosis to the date progressive disease was defined and also patient was alive, assessed up to 2 years
Safety Issue:
Description:Calculated using the Kaplan-Meier method.

Details

Phase:Phase 1
Primary Purpose:Interventional
Overall Status:Active, not recruiting
Lead Sponsor:National Cancer Institute (NCI)

Last Updated

February 12, 2021